Annals of Oncology 13:819-829, 2002
© 2002 European Society for Medical Oncology
Review Article |
Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review
Academic Medical Centre, Emma Kinder Ziekenhuis, University of Amsterdam, Departments of 1Pediatric Oncology, 2Medical Oncology and 3Pediatrics, Amsterdam, The Netherlands
Received 2 January 2002; accepted 16 January 2002.
Abstract
Background
The aim of this systematic review was to summarise and appraise the published evidence with regard to the frequency and risk factors of subclinical cardiotoxicity in apparently healthy survivors of childhood cancer after anthracycline therapy.
Patients and methods
A search was made in Medline for studies published between 1966 and May 2001 that included >50 children and reported on the frequency of measures of subclinical cardiotoxicity. Information about the studies was abstracted by two reviewers and a validity score was calculated for each study.
Results
The reported frequency of subclinical cardiotoxicity varied between 0% and 57% in the 25 studies included. Differences in outcome definitions of subclinical cardiotoxicity and differences in study patients with respect to the dose of anthracycline seemed to explain part of the wide variance of the frequency of subclinical cardiotoxicity. Fourteen of the 25 studies showed serious methodological limitations.
Conclusions
The reported frequency of subclinical cardiotoxicity shows a wide variation. Well designed studies with accurate and precise outcome measurements in well described groups of patients, after a sufficiently long follow-up period, are needed to obtain more insight into the frequency and importance of risk factors, and the clinical consequences of anthracycline-related subclinical cardiotoxicity.
Key words: anthracyclines, cardiotoxicity, children, heart, systematic review, systolic function
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Huang, X. Zhang, J. M. Ramil, S. Rikka, L. Kim, Y. Lee, N. A. Gude, P. A. Thistlethwaite, M. A. Sussman, R. A. Gottlieb, et al. Juvenile Exposure to Anthracyclines Impairs Cardiac Progenitor Cell Function and Vascularization Resulting in Greater Susceptibility to Stress-Induced Myocardial Injury in Adult Mice Circulation, February 9, 2010; 121(5): 675 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A Mulrooney, M. W Yeazel, T. Kawashima, A. C Mertens, P. Mitby, M. Stovall, S. S Donaldson, D. M Green, C. A Sklar, L. L Robison, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort BMJ, December 8, 2009; 339(dec08_1): b4606 - b4606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Shankar, N. Marina, M. M. Hudson, D. C. Hodgson, M. J. Adams, W. Landier, S. Bhatia, K. Meeske, M. H. Chen, K. E. Kinahan, et al. Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group Pediatrics, February 1, 2008; 121(2): e387 - e396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Villella Monitoring Survivors of Childhood AML for Anthracycline Cardiotoxicity AAP Grand Rounds, December 1, 2007; 18(6): 62 - 63. [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Carver, C. L. Shapiro, A. Ng, L. Jacobs, C. Schwartz, K. S. Virgo, K. L. Hagerty, M. R. Somerfield, D. J. Vaughn, and for the ASCO Cancer Survivorship Expert Panel American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects J. Clin. Oncol., September 1, 2007; 25(25): 3991 - 4008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. P. Aleman, A. W. van den Belt-Dusebout, M. L. De Bruin, M. B. van 't Veer, M. H. A. Baaijens, J. P. d. Boer, A. A. M. Hart, W. J. Klokman, M. A. Kuenen, G. M. Ouwens, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma Blood, March 1, 2007; 109(5): 1878 - 1886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Zaya, R. N. Hines, and J. C. Stevens Epirubicin Glucuronidation and UGT2B7 Developmental Expression Drug Metab. Dispos., December 1, 2006; 34(12): 2097 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E De Caro, F Fioredda, M G Calevo, A Smeraldi, M Saitta, G Hanau, M Faraci, F Grisolia, G Dini, G Pongiglione, et al. Exercise capacity in apparently healthy survivors of cancer Arch. Dis. Child., January 1, 2006; 91(1): 47 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Oeffinger and M. M. Hudson Long-term Complications Following Childhood and Adolescent Cancer: Foundations for Providing Risk-based Health Care for Survivors CA Cancer J Clin, July 1, 2004; 54(4): 208 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Hequet, Q.H. Le, I. Moullet, E. Pauli, G. Salles, D. Espinouse, C. Dumontet, C. Thieblemont, P. Arnaud, D. Antal, et al. Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults J. Clin. Oncol., May 15, 2004; 22(10): 1864 - 1871. [Abstract] [Full Text] [PDF]
|
|